Geluk Annemieke, van der Ploeg-van Schip Jolien J, van Meijgaarden Krista E, Commandeur Susanna, Drijfhout Jan W, Benckhuijsen Willemien E, Franken Kees L M C, Naafs Bernard, Ottenhoff Tom H M
Department of Infectious Diseases, LUMC, P.O. Box 9600, 2300 RC Leiden, Netherlands.
Clin Vaccine Immunol. 2010 Jun;17(6):993-1004. doi: 10.1128/CVI.00046-10. Epub 2010 Apr 28.
Although worldwide leprosy prevalence has been reduced considerably following multidrug therapy, new case detection rates remain relatively stable, suggesting that transmission of infection still continues. This calls for new efforts, among which is development of assays that can identify subclinical/early-stage Mycobacterium leprae-infected subjects, a likely source of transmission. Areas in which leprosy is endemic often lack sophisticated laboratories, necessitating development of field-friendly immunodiagnostic tests for leprosy, like short-term whole-blood assays (WBA). In classical, peripheral blood mononuclear cell (PBMC)-based gamma interferon (IFN-gamma) release assays, M. leprae peptides have been shown to discriminate in a more specific fashion than M. leprae proteins between M. leprae-exposed contacts and patients as opposed to healthy controls from the same area of endemicity. However, peptides induced significantly lower levels of IFN-gamma than did proteins, particularly when whole blood was used. Therefore, possibilities of specifically enhancing IFN-gamma production in response to M. leprae peptides in 24-h WBA were sought by addition of various cytokines and antibodies or by mannosylation of peptides. In addition, other cytokines and chemokines were analyzed as potential biomarkers in WBA. We found that only interleukin 12 (IL-12), not other costimulants, increased IFN-gamma production in WBA while maintaining M. leprae peptide specificity, as evidenced by lack of increase of IFN-gamma in control samples stimulated with IL-12 alone. The IL-12-induced increase in IFN-gamma was mainly mediated by CD4+ T cells that did not produce IL-2 or tumor necrosis factor (TNF). Mannosylation further allowed the use of 100-fold-less peptide. Although not statistically significantly, macrophage inflammatory protein 1beta (MIP-1beta) and macrophage c protein 1 (MCP-1) levels specific for M. leprae peptide tended to be increased by IL-12. IP-10 production was also found to be a useful marker of M. leprae peptide responses, but its production was enhanced by IL-12 nonspecifically. We conclude that IFN-gamma-based WBA combined with IL-12 represents a more sensitive and robust assay for measuring reactivity to M. leprae peptides.
尽管在采用多药疗法后全球麻风病患病率已大幅降低,但新病例发现率仍相对稳定,这表明感染传播仍在继续。这就需要做出新的努力,其中包括开发能够识别亚临床/早期麻风分枝杆菌感染个体的检测方法,这些个体很可能是传播源。麻风病流行地区往往缺乏先进的实验室,因此有必要开发对现场条件友好的麻风病免疫诊断检测方法,如短期全血检测(WBA)。在经典的基于外周血单核细胞(PBMC)的γ干扰素(IFN-γ)释放检测中,已表明麻风分枝杆菌肽在区分麻风分枝杆菌暴露的接触者和患者方面比麻风分枝杆菌蛋白更具特异性,与来自同一流行地区的健康对照相比。然而,肽诱导的IFN-γ水平明显低于蛋白质,特别是在使用全血时。因此,通过添加各种细胞因子和抗体或对肽进行甘露糖基化,寻求在24小时WBA中特异性增强对麻风分枝杆菌肽反应的IFN-γ产生的可能性。此外,还分析了其他细胞因子和趋化因子作为WBA中的潜在生物标志物。我们发现,只有白细胞介素12(IL-12),而不是其他共刺激剂,能增加WBA中IFN-γ的产生,同时保持麻风分枝杆菌肽的特异性,这一点通过单独用IL-12刺激的对照样品中IFN-γ没有增加得到证明。IL-12诱导的IFN-γ增加主要由不产生IL-2或肿瘤坏死因子(TNF)的CD4 + T细胞介导。甘露糖基化进一步使得肽的用量可减少100倍。虽然没有统计学显著差异,但IL-12倾向于增加对麻风分枝杆菌肽特异的巨噬细胞炎性蛋白1β(MIP-1β)和巨噬细胞趋化蛋白1(MCP-1)水平。还发现IP-10的产生是麻风分枝杆菌肽反应的一个有用标志物,但其产生被IL-12非特异性增强。我们得出结论,基于IFN-γ的WBA与IL-12相结合代表了一种更敏感、更可靠的检测方法,用于测量对麻风分枝杆菌肽的反应性。